Bristol’s Phase III Opdivo Data Clarify PD-1’s Place In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In the first randomized Phase III results for a PD-1 inhibitor to be presented at a major medical meeting, Bristol reports a 32% response rate for nivolumab compared to 11% for investigator’s choice of therapy in relapsed melanoma. Bristol immunotherapy exec Michael Giordano says the jury’s still out on PD-L1 as a predictive biomarker.